EVALUATION OF A TRANS CONFIGURATION FOR THE APOPTOSIS-INDUCING ACTIVITY OF CERAMIDE

Citation
E. Kishida et al., EVALUATION OF A TRANS CONFIGURATION FOR THE APOPTOSIS-INDUCING ACTIVITY OF CERAMIDE, Journal of lipid mediators and cell signalling, 16(3), 1997, pp. 127-137
Citations number
33
Categorie Soggetti
Biology,"Cell Biology
ISSN journal
09297855
Volume
16
Issue
3
Year of publication
1997
Pages
127 - 137
Database
ISI
SICI code
0929-7855(1997)16:3<127:EOATCF>2.0.ZU;2-6
Abstract
The requirement of a trans double bond for the biological action of ce ramide was assessed by comparing the apoptosis-inducing activity of va rious ceramide analogs, The cis isomer and an acetylene type derivativ e of sphingosine were chemically synthesized, and the 2-amino moiety w as acylated with hexanoic acid, These cell-permeable ceramide derivati ves were compared with N-hexanoyl sphingosine (C-6-Cer) or N-hexanoyl dihydrosphingosine (C-6-DH-Cer) in their activity to induce apoptosis of HL60. Either the cis isomer of C-6-Cer (C-6-cis-Cer) or a triple bo nd derivative (C-6-TRP-Cer) induced apoptosis when assessed by fluores cence microscopy of the morphological changes and electrophoretic anal ysis of DNA C-6-TRP-Cer yielded the highest percentage of apoptotic ce lls corresponding to three times that was induced by C-6-Cer. C-6-cis- Cer also showed stronger activity than C-6-Cer. The minimum amounts of C-6-TRP-Cer and C-6-cis derivative required to induce apoptosis were 0.1 and 0.5 mu M, respectively, while 1 mu M C-6-Cer was required to e xhibit the activity. C-6-DH-Cer showed very low but significant activi ty above 10 mu M. N- acetyl - sphingosine (C-2-Cer) induced more apopt otic cells than C-6-Cer, and C-2-TRP-Cer wets much more potent than C- 2-Cer. These observations suggest that the trans configuration of cera mide is not necessarily essential for the activity to induce apoptosis . In addition, distinctive activity of C-6- or C-2-TRP-Cer suggests th at this ceramide analog might be useful For developing a new type of a ntitumor drug. (C) 1997 Elsevier Science B.V.